gp130 at the nexus of inflammation, autoimmunity, and cancer

• Published in: Journal of leukocyte biology Vol. 88; no. 6; pp. 1145 - 1156
• Main Authors: Silver, J. S., Hunter, C. A.
• Format: Journal Article
• Language: English
• Published: United States Society for Leukocyte Biology 01-12-2010
• Subjects: Animals; Arthritis, Rheumatoid - drug therapy; Asthma - immunology; Autoimmunity; B-Lymphocytes - immunology; Cytokine Receptor gp130 - physiology; Encephalomyelitis, Autoimmune, Experimental - immunology; Humans; IL‐11; IL‐27; IL‐6; Inflammation - etiology; Inflammation - immunology; Interleukin-6 - antagonists & inhibitors; Interleukin-6 - physiology; Neoplasms - etiology; Neoplasms - immunology; Neoplasms - prevention & control; oncostatin M; Reviews; Signal Transduction; STAT Transcription Factors - physiology; STAT3; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins - physiology
• ISSN: 0741-5400; 1938-3673
• DOI: 10.1189/jlb.0410217

Review highlights the function of the cytokine receptor gp130, specifically the diverse roles it plays in inflammation, autoimmunity, and cancer.
Glycoprotein 130 (gp130) is a shared receptor utilized by several related cytokines, including IL‐6, IL‐11, IL‐27, Leukemia Inhibitory Factor (LIF), Oncostatin M (OSM), Ciliary Neurotrophic Factor (CNTF), Cardiotrophin 1 (CT‐1) and Cardiotrophin‐like Cytokine (CLC). Gp130 plays critical roles during development and gp130‐deficient mice are embryonically lethal. However, the best characterized facet of this receptor and its associated cytokines is the ability to promote or suppress inflammation. The aim of this review is to discuss the role of gp130 in promoting or preventing the development of autoimmunity and cancer, two processes that are associated with aberrant inflammatory responses.